861605-94-9

Basic information

• Product Name: 4-bromo-2-phenoxybenzoic acid
• Synonyms: 4-bromo-2-phenoxybenzoic acid
• CAS NO: 861605-94-9
• Molecular Formula: C13H9BrO3
• Molecular Weight: 293.117
• Mol File: 861605-94-9.mol

Chemical Properties

• CAS DataBase Reference: 4-bromo-2-phenoxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-2-phenoxybenzoic acid(861605-94-9)
• EPA Substance Registry System: 4-bromo-2-phenoxybenzoic acid(861605-94-9)

Safety Data

• Hazardous Substances Data: 861605-94-9(Hazardous Substances Data)

Upstream product

• 611-00-7 2,4-dibromobenzoic acid 
• 139-02-6 sodium phenoxide 
• 59748-90-2 4-Bromo-2-chloro-benzoic Acid 
• 108-95-2 phenol 
• 540-38-5 p-Iodophenol 
• 118-55-8 phenyl Salicylate 
• 2243-42-7 2-phenoxybenzoic acid 
• 1133123-02-0 4-bromo-2- iodobenzoic acid 
• 1093418-75-7 methyl 4-bromo-2-iodobenzoate 
• 20776-50-5 2-amino-4-bromobenzoic acid 
• 1016313-33-9 C₁₄H₁₁BrO₃ 
• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 78471-43-9 methyl 4-bromo-2-(bromomethyl)benzoate 
• 875664-25-8 4-bromo-2-phenoxy-benzonitrile 

Downstream Products

• 500286-36-2 3-bromo-9H-xanthene-9-one 
• 99515-51-2 phenyl 4-bromo-2-hydroxybenzoate 
• 26608-06-0 3-bromodibenzofuran 

Relevant articles and documents

Electrochemical Reductive Smiles Rearrangement for C-N Bond Formation

A conceptually new and synthetically valuable radical Smiles rearrangement reaction is reported under undivided electrolytic conditions. This protocol employs an entirely new strategy for the electrochemical radical Smiles rearrangement. Remarkably, an amidyl radical generated from the cleavage of the N-O bond under reductive electrolytic conditions plays a crucial role in this transformation. Various hydroxylamine derivatives bearing different substituents are suitable in this electrochemical transformation, furnishing the corresponding amides in up to 86% yield.

Anthraquinone general formula compound and application thereof

The invention discloses an anthraquinone general formula compound and application thereof. The general formula compound is shown in a formula in the specification, in the formula, Y represents an oxygen atom or a sulfur atom, X1 to X8 represent C, CR or N

Anthraquinone organic electroluminescent material and application thereof

The invention discloses an anthraquinone organic electroluminescent material and application thereof. A general formula compound is shown in a formula (1) in the specification, and in the formula (1),Z is selected from O or S; X1-X8 are independently selected from CR1 or N, wherein R1 is selected from a structure shown in a formula (2) in the specification, or selected from hydrogen, alkyl, arylor heterocyclic aryl, adjacent R1 groups can form a ring, and at least one of R1 groups is selected from the structure (2) shown in the formula (2); in the formula (2), Y1-Y8 are independently selected from CR2 or N, and at least one of the Y1-Y8 is selected from N; R2 is selected from hydrogen, alkyl, aryl or heterocyclic aryl, and adjacent R2 groups can form a ring; L is selected from single bonds, arylidene or heterocyclic arylidene; and when two or more R1 groups are selected from the formula (2), the selected L groups in the formula (2) are not single bonds at the same time. The compoundshows excellent device performance and stability when serving as the light-emitting material in an organic light-emitting device (OLED), and meanwhile the OLED adopting the general formula compound iswithin the scope of right protection.

Aza-spirofluorene anthracene heterocyclic compound and application thereof in organic electroluminescence elements

The invention relates to an aza-spirofluorene anthracene heterocyclic compound and an application thereof in organic electroluminescence elements. The aza-spirofluorene anthracene heterocyclic compound is represented by a general formula (1) (shown in the description), wherein groups of furan, carbazole, thiophene, fluorine, heteraryl amino, acridine, phenazine and the like are linked to a matrixof the compound. According to the aza-spirofluorene anthracene heterocyclic compound, the transmission property of a current carrier can be improved, the triplet state energy of a material can be improved, the HOMO/LUMO value of the material can be optimized, the high brightness, low voltage, high efficiency and long service life of an organic EL element can be realized, meanwhile, the material prepared from the compound has relatively high heat stability, the luminescence stability of a light emitting device can be remarkably improved, and the compound can be widely used as a luminescent layer main body material for OLED light emitting devices and display devices.

A photoredox-neutral Smiles rearrangement of 2-aryloxybenzoic acids

We report on the use of visible light photoredox catalysis for the radical Smiles rearrangement of 2-aryloxybenzoic acids to obtain aryl salicylates. The method is free of noble metals and operationally simple and the reaction can be run under mild batch or flow conditions. Being a redox neutral process, no stoichiometric oxidants or reductants are needed.

Efficient Aryl Migration from an Aryl Ether to a Carboxylic Acid Group To Form an Ester by Visible-Light Photoredox Catalysis

We have developed a highly efficient aryl migration from an aryl ether to a carboxylic acid group through retro-Smiles rearrangement by visible-light photoredox catalysis at ambient temperature. Transition metals and a stoichiometric oxidant and base are avoided in the transformation. Inspired by the high efficiency of this transformation and the fundamental importance of C?O bond cleavage, we developed a novel approach to the C?O cleavage of a biaryl ether to form two phenolic compounds, as demonstrated by a one-pot, two-step gram-scale reaction under mild conditions. The aryl migration exhibits broad scope and can be applied to the synthesis of pharmaceutical compounds, such as guacetisal. Primary mechanistic studies indicate that the catalytic cycle occurs by a reductive quenching pathway.

FUSED RING INHIBITORS OF HEPATITIS C

Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C.

TRICYCLIC DELTA- OPIOID MODULATORS

The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators, of formula (I). Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

Tricyclic delta-opioid modulators

The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using com

Tricyclic delta-opioid modulators

The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.